Deborah Kahal
Infectious Disease · Wilmington, DENPI 1821227315
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,763 of the $108,750 with a category attached, or 80.7%. Gilead accounts for 72.9% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $25,894, 2.4 times the $10,638 reported in 2019. Among infectious disease clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $594.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$79K
- Viiv Healthcare Company$29K
- AbbVie$129
- Merck$84
- Exact Sciences$82
- Lilly USA, LLC$41
- plus $149 from 7 others
What the payments were for
- Consulting fees$12,29011%
- Speaking & faculty fees$87,76381%
- Travel & lodging$5,2075%
- Food & beverage$3,4593%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 117 | $79,264 |
| Viiv Healthcare Company | 42 | $29,000 |
| AbbVie | 7 | $129 |
| Merck | 4 | $84 |
| Exact Sciences | 4 | $82 |
| Lilly USA, LLC | 2 | $41 |
| Janssen Products, LP | 1 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $20 |
| GSK | 1 | $17 |
| Theratechnologies Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,750 in reported general payments places this provider in the 95th percentile of 28 infectious disease providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 27 | $109,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $79,264 | $109,67627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 infectious disease providers in Delaware.
Other infectious disease in Wilmington
- Kirsten HauerWilmington$9K
- William MazurWilmington$3K
- Wayne DuffusWilmington$581
- Robert JakubowskiWilmington$194
- Susan SzaboWilmington$28
- Jimmy ChuaLewes$18K
- Ramesh VemulapalliDover$4K
- Wesley EmmonsNewark$4K
- Maya GuptaNewark$2K
- Makondo ShimukowaDelmar$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.